Stifel Maintains Buy on Disc Medicine, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett has maintained a Buy rating on Disc Medicine (NASDAQ:IRON) and increased the price target from $71 to $73.
April 08, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Benjamin Burnett reaffirms a Buy rating on Disc Medicine and raises the price target from $71 to $73.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100